Alex Marcheschi

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial

Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary et autres

COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study’s pre-crossover/booster phase were previously reported. This phase 2a/b clinical trial in …

us, Afrique du Sud, Nigéria, mx, cz (code pays fourni par la source)

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

Chijioke Bennett, Wayne Woo, Mark Bloch, King Cheung et autres

us, au (code pays fourni par la source)

2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial

Chijioke Bennett, Wayne Woo, Alex Marcheschi, Raburn M. Mallory

Abstract Background Currently circulating Omicron subvariants contain mutations permitting evasion of neutralization with prototype vaccines. Novel Omicron BA.1 (NVX-CoV2515) and Omicron BA.5 (NVX-CoV2540) subvariant-specific vaccines were tested alone or as bivalent preparations combined with the prototype vaccine (NVX-CoV2373) to determine if superior …

us (code pays fourni par la source)

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial

Chijioke Bennett, Elizabeth J Rivers, Wayne Woo, Mark Bloch et autres

BACKGROUND: Mutations present in emerging SARS-CoV-2 variants permit evasion of neutralization with prototype vaccines. A novel Omicron BA.1 subvariant-specific vaccine (NVX-CoV2515) was tested alone, or as a bivalent preparation in combination with the prototype vaccine (NVX-CoV2373), to assess antibody responses to SARS-CoV-2. …

us, au (code pays fourni par la source)

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

Chijioke Bennett, Elizabeth J Rivers, Wayne Woo, Mark Bloch et autres

Abstract Background Mutations present in emerging SARS-CoV-2 variants permit evasion of neutralization with prototype vaccines. A novel Omicron BA.1 subvariant-specific vaccine (NVX-CoV2515) was tested alone, or as a bivalent preparation in combination with the prototype vaccine (NVX-CoV2373), to assess antibody responses to …

us, au, gb, at (code pays fourni par la source)

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373

Katia Alves, Joyce S. Plested, Shirley Galbiati, Gordon Chau et autres

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant spike [rS] protein + 50 µg Matrix-M™ adjuvant; Novavax, Gaithersburg, MD) was evaluated …

us (code pays fourni par la source)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

Katia Alves, Joyce S. Plested, Shirley Galbiati, Gordon Chau et autres

us (code pays fourni par la source)

Immunogenicity and safety of a 4 th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial

Katia Alves, Joyce S. Plested, Shirley Galbiati, Gordon Chau et autres

Summary Background The emergence of SARS-CoV-2 variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5µg SARS-CoV-2 rS + 50µg Matrix-M™ adjuvant) was evaluated to determine induction of cross-reactive antibodies to variants of concern. Methods A …

us (code pays fourni par la source)

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil T. Formica, Susan Pfeiffer, Bethanie E. Wilkinson et autres

us (code pays fourni par la source)

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

Raburn M. Mallory, Neil T. Formica, Susan Pfeiffer, Bethanie E. Wilkinson et autres

SUMMARY Background Emerging SARS-CoV-2 variants and evidence of waning vaccine efficacy present significant obstacles toward controlling the COVID-19 pandemic. Booster doses of SARS-CoV-2 vaccines may address these concerns by both amplifying and broadening the immune responses seen with initial vaccination regimens. Methods …

us (code pays fourni par la source)